Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results The company is developing the therapy for treatment of agitation associated with the condition

https://www.statnews.com/2024/12/30/axsome-therapeutics-alzheimers-disease-drug-trial-results/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz--ySJLo4VRq7PENZ3h5Vt4toKD_oHU7XEPqBSvn_r_ytnRQbiA012zmZQmX300bNOgUKZsh-_1DDTsnrBXL8k8y8KJ7FQ&_hsmi=340542835&utm_content=340542835&utm_source=hs_email